Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression - In Vivo Validation
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Free. Verify your email, then we send one reminder only.
- Posted
- Aug 27, 2026
- Closes
- Rolling, no fixed deadline
Similar opportunities open now
- Notice of Ordering Period Extension-Clinical Evaluation of Phenserine Tartrate Extended Controlled Release TabletSame funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFNo deadline listed
- Notice of Intent to Award a Sole Source Commercial Simplified Acquisition Procedures (SAP) Contract for Development of a Human Neural Network Formation New Approach Method for the Evaluation of Potential Developmental NeurotoxicitySame funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFNo deadline listed
- AJ13--Pharmarcokinetics for Experimental Rheumatoid Arthritis treatmentOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- AJ11--Pharmacokinetic StudiesOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- Acquisition of a High-Sensitivity Preclinical Quantitative microSPECT Imaging SystemSame funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFNo deadline listed
At a glance
This is a government contract opportunity posted by HEALTH AND HUMAN SERVICES, DEPARTMENT OF in the research and development in biotechnology (except nanobiotechnology) category. Applications are accepted on a rolling basis.
Classification and identifiers
- Industry (NAICS)
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- Product or service (PSC)
- Health R&D Services; Health Care Services; Applied Research (AN12)
- Solicitation number
- 75F40126Q00382
- Contracting office
- FDA OFFICE OF ACQ GRANT SVCS
Who can apply
About this opportunity
Title: Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation Agency: U.S. Food and Drug Administration (FDA) Notice Type: Presolicitation: Firm-Fixed Price DEA surveillance data show that street fentanyl is frequently adulterated with xylazine, d-methamphetamine, or alprazolam — each of which induces respiratory depression through a distinct mechanism. Approximately 80% of opioid overdose cases involve multiple drugs, yet naloxone — the primary FDA-approved reversal agent — was developed and tested for opioid-only scenarios. This mechanistic complexity creates uncertainty about naloxone's efficacy in polysubstance overdose and raises the question of what alternative or adjunct therapies may be needed. Drug-induced respi...